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Abstract
Background: ΔNp63, a splice variant of p63, is overexpressed and exhibits oncogenic activity in many cancers
including pancreatic and breast cancer and promotes cell survival by inhibiting apoptosis. Despite its role in
tumorigenesis, mechanistic activity of ΔNp63 mediated oncogenic function in osteosarcoma is poorly understood.
Methods: The expression levels of p63 isoforms in osteosarcoma cell lines were identified using quantitative
techniques. Expression profiling using microarray, siRNA mediated loss-of-function, and chromatin immunoprecipitation
assays were employed to identify novel ΔNp63α targets in p63-null osteosarcoma SaOS-2 cells that were engineered to
express ΔNp63α. The phenotype of SaOS-2-ΔNp63α cells was assessed using wound-healing, colony formation, and
proliferation assays.
Results: The comparative expression analyses identified ΔNp63α as the predominant p63 isoform expressed by
invasive OS cell lines. Phenotypic analyses of SaOS-2-ΔNp63α cells in vitro indicate that ΔNp63α imparted tumorigenic
attributes upon tumor cells. Further, we show that in osteosarcoma cells ΔNp63α directly regulated the transcription
factor GLI2, which is a component of the hedgehog signaling pathway, and that functional interactions between
ΔNp63α and GLI2 confer oncogenic properties upon OS cells.
Conclusions: Here, we report that GLI2 is the novel target gene of ΔNp63α and that ΔNp63α-GLI2 crosstalk in
osteosarcoma cells is a necessary event in osteosarcoma progression. Defining the exact mechanisms involved in
this interaction that mediate the pathogenesis of osteosarcoma promises to identify targets for drug therapy.
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Background
Osteosarcoma (OS) is a highly malignant bone tumor
with an increased prevalence in children and young
adults. OS commonly occurs in the metaphysis of long
bones adjacent to the growth plates where bone growth
occurs during puberty. Osteosarcomas are generated by
malignant transformation of mesenchymal cells, which
normally differentiate to osteoid- and bone-forming cells
[1]. The majority of patients with newly diagnosed OS suf-
fer from localized disease and up to 70% survive with
state-of-the-art treatment, which comprises local surgical
control of the primary tumor combined with neoadjuvant
multidrug chemotherapy [2]. Unfortunately, 15–30% of
OS patients present with metastases at diagnosis and their
5 year survival rate is only approximately 20% regardless
of therapy [3]. Thus, the pathogenesis of OS requires fur-
ther research to develop more effective treatment of meta-
static disease.
The p63 gene, a member of p53 gene family, encodes the
isoforms TAp63 and ΔNp63 [4]. TAp63 and ΔNp63 are
transcribed from two distinct p63 promoters- P1 and P2
and they are differentially spliced at their C- termini to
generate the variants α, β, γ, Δ and ε [5]. The “long” iso-
forms are collectively described as TAp63, contain an
N-terminal transactivation (TA) domain and suppress
tumorigenesis and metastasis. Mice lacking TAp63 develop
spontaneous carcinomas, sarcomas, tumors of the bone,
fat, and cartilage supporting the conclusion that TAp63
is a tumor suppressor [6]. In contrast, the “short”
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isoforms collectively described as ΔNp63, which lack
the TA domain, exert oncogenic properties and overex-
pression of ΔNp63 promotes cell proliferation in vitro
and tumor growth in vivo of many cancers [7]. The
proteins encoded by p63, unlike p53, mediate the de-
velopment and differentiation of epithelial surfaces and
act as oncogenes or tumor suppressors depending on
the cell type [8].
Studies on epigenetic modifications and expression of
genes involved in cell proliferation and metastasis indi-
cate that genomic instability is a hallmark of OS. Stud-
ies on the role of ΔNp63 in the regulation of cell
proliferation and in the cell cycle led to the hypothesis
that up-regulation of ΔNp63 expression might counter-
act p53 functions thereby explaining the oncogenic ef-
fects of ΔNp63 [5,7]. However, the tumorigenic effects
of ΔNp63 may also be mediated by promoting the
transactivation of target genes such as those encoding
Lsh, which is a chromatin remodeler, involved in
tumorigenesis and stem cell proliferation as well as
genes encoding interleukin (IL)- 6 and (IL)-8 that are
involved in tumor angiogenesis associated with neuro-
blastomas and osteosarcomas [9,10]. ΔNp63α is the
most abundant p63 isoform expressed in cancer cells
[11] and is overexpressed in squamous cell carcinoma
which enhances cell growth by counteracting p53-
mediated growth arrest and apoptosis [12].
ΔNp63 isoforms are predominantly expressed in blad-
der carcinomas, non-small cell lung cancers and liver
cancers among others, indicating their role in carci-
nogenesis. These findings are surprising, because their
expression is undetectable in breast and prostate adeno-
carcinomas [13]. Moreover, ΔNp63α is implicated in OS
progression and is involved in tumor angiogenesis [10].
Independent of p53 mutational status, frequent up-
regulation of ΔNp63α in OS increases the levels of IL-6
and IL-8 that induce increased phosphorylation of signal
transducer and activator of transcription 3 (STAT-3) to
promote oncogenesis. Moreover, the levels of ΔNp63α in
lung metastases of patients with OS are higher com-
pared with corresponding primary lesions in the same
patients [10].
In vivo studies using short hairpin RNA mediated
knockdown of ΔNp63 expression showed that the
tumor volume in mice decreased significantly com-
pared with control mice carrying tumors transduced
with control shRNA [10]. However, the mechanism
that regulates the expression of p63 in OS particularly
the ΔNp63 isoforms is unknown. Here, we provide new
insights into the mechanism that controls the ability of
ΔNp6α to enhance the malignant phenotype of OS
cells and show that the expression of GLI2, a transcrip-
tional activator and mediator of the Hedgehog (HH)
signaling pathway, is regulated by ΔNp63α.
Methods
Cell culture and reagents
The human OS cell lines SaOS-2 (HTB-85), U2OS
(HTB-96), HOS and 143B were obtained from the
American Type Culture Collection (Manassas, VA,
USA). The SaOS-2, LM5 was provided by E.S. Kleinerman
(M.D. Anderson Cancer Center, Houston, TX, USA).
Hu09 cells and the Hu09-M132 subline were provided
by Dr. M. Tani (National Cancer Center Hospital,
Tokyo, Japan), MG-63 cells were provided by Dr. G.
Sarkar (Mayo Clinic, Rochester, MN, USA) and the
MG-63 subline M8 was provided by Dr. W.T. Zhu
(Tongji Hospital, Huazhong University of Science and
Technology, Wuhan, China). All cell lines were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM
containing 4.5 g/l glucose)/Ham F12 (Invitrogen,
Carlsbad, CA, USA) (1:1) supplemented with 10% fetal
calf serum (FCS). All cells were cultured at 37°C in a
humidified atmosphere of 5% CO2. BxPC3 cell lines
were kindly provided by Dr. Corina Kim Fuchs (Inselspital
Bern, Switzerland). The cells were cultured in RPMI 1640
medium containing 10% FCS and then incubated at 37°C
in an atmosphere containing 5% CO2. The invasive cell
lines LM5 and M132 were derived from the SAOS and
HUO9 cell lines by repeated intravenous injections of
mice with cells isolated sequentially from lung metastases.
The 143B cell line was generated by transforming HOS
cells with K-ras and the M8 cell line was generated by
in vitro sub cloning of MG63 cells [14-17]. GANT61 was
purchased from Bio vision Inc. (San Francisco, USA). For
p63 knock-down experiments 143B and M132 cells were
transiently transfected with Lipofectamine LTX reagent
(Life Technologies, USA).
Tissue microarray construction
All the tissues were fixed in 4% formaldehyde and em-
bedded in paraffin. Paraffin-embedded donor tissue
blocks were sampled using a Manual Tissue Arrayer 1
instrument (Beecher Instruments, Silver Spring, MA,
USA). Sections were cut for hematoxylin-eosin stain-
ing and histopathologically representative tumor re-
gions were used for preparation of TMA blocks. After
the TMA construction, sections were cut from the
“donor” blocks comprising of 61 tumor biopsies and 55
tumor resections having sufficient material available.
Sections (5 μm) of the tissue array block were cut and
placed on polylysine-coated glass slides and processed
for immunohistochemical staining (IHC) with rabbit
anti-ΔNp63 (1:500). The tissue cores were graded by
two independent trained researchers. The cores were
considered negative if less than 50% of the cells were
stained with ΔNp63 and if the staining is seen in more
than 50% of the cells, the cores were considered as
positive for ΔNp63.
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Retroviral transduction of cell lines
Constructs for stable constitutive expression of TAp63α,
TAp63γ, ΔNp63α and ΔNp63γ were provided by
Maranke Koster (University of Colorado, Denver, USA)
and were cloned using the pQCXIH vector. Retroviral
particles containing the described constructs were pro-
duced in HEK293-T cells according to a published method
[18]. Briefly, HEK293-T cells were cultured in Advanced
D-MEM medium (GIBCO) supplemented with 2% fetal
calf serum and a culture additive containing 0.01 mM
cholesterol (Sigma-Aldrich), 0.01 mM egg yolk lecithin
(Serva Electrophoresis GmbH, Heidelberg, Germany) and
1x chemically defined lipid concentrate (GIBCO) (trans-
fection medium). The cells were co-transfected using the
calcium phosphate method with the following three
plasmids: a retroviral expression vector together with
the two helper plasmids pVSV-G (Clontech), encoding
the G-glycoprotein of the vesicular stomatitis virus, and
pHit60 encoding the retroviral gag and pol genes (pro-
vided by Dr. Christian Buchholz, Paul-Ehrlich- Institute,
Langen, Germany). Fourteen hours after transfection the
medium was replaced with fresh transfection medium.
The supernatant containing each recombinant retrovirus
was collected 48 h after transfection, filtered through a
0.45 μm syringe filter and stored in aliquots at − 80°C.
cDNA synthesis and expression analysis
Total RNA was isolated from cell lines using an RNeasy
mini kit (Qiagen, Valencia, CA, USA), and 1 μg of RNA
was used as template for cDNA synthesis using a High-
Capacity cDNA reverse transcription kit (Applied Bio-
systems, Foster City, CA, USA). Semi-quantitative PCR
amplification of each p63 isoform was performed using
primers described previously [19]. PCR was performed
as follows: denaturation at 94°C for 3 min, 35 cycles of
incubation at 94°C for 40 s and at 55°C for 40 s and in-
cubation at 72°C for 4 min. For real time PCR (qRT-
PCR) analysis three independent RNA preparations from
each cell lines were reverse transcribed in a final volume
of 10 μl. qRT-PCR was performed using the StepOne
Plus Real- Time PCR system (Applied Biosystems, USA)
in 96 well plates. Primers (Additional file 1) used to
amplify cDNAs were designed using NCBI-primer soft-
ware (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
PCR amplification of individual qRT-PCR reactions were
carried out in triplicate. The cDNA and appropriate
primers were added to Power SYBR Green PCR master
mix (Applied Biosystems, USA) and the samples were
pre-incubated as follows: 50°C for 2 min and at 95°C for
10 min, 40 cycles at 95°C for 15 s and at 60°C for 1 min.
The threshold of Ct values was set to 0.325. To verify the
amplification of a single product in any of the PCR reac-
tions, a melting curve was generated and analysed after
every run. Relative expression levels were calculated by
the comparative cycle threshold (ΔΔCT) method and were
normalized to GAPDH expression.
Microarray analysis
Complementary RNA preparation and array hybri-
dization were performed at the Functional Genomics
Center of the University of Zurich, using the Agilent
SurePrint Human Gene Expression 8 × 60K array. Genes
with a False Discovery Rate with an adjusted P value <
0.005 and a fold change (fc) > 2 were considered dif-
ferentially expressed. To identify specific genes expressed
in samples transfected with ΔNp63α compared with the
empty vector, we used a computer algorithm that allowed
us to select genes exhibiting ≥ 3 fold changes. Genes
expressed at ≥ 3 fold levels in SaOS-2-EV and SaOS-2-
ΔNp63α cells were aligned using a computer algorithm
and Microsoft Excel. Three replicas of each sample were
analysed and genes that showed a common pattern of fc
in each of the three individual experiments were se-
lected for further analysis. Enrichment analysis was per-
formed on the web platform, Database for Annotation,
Visualization and Integrated Discovery (DAVID 2.0;
http://david.abcc.ncifcrf.gov/). Functional annotates ac-
quired from the list of regulated genes and the probe
sets that identified multiple transcripts were removed.
From DAVID analysis, we selected the pathways of
Kyoto Encyclopaedia of Genes and Genomes (KEGG
pathway) that include a compilation of the network of
molecular interactions in cells. The micro array data
have been deposited in the Gene Expression Omnibus
(Accession No: GSE54942).
Western blot analysis
Cells were lysed by agitation on a rotating platform at
4°C for 1 hour in lysis buffer containing 50 mM Tris/
HCl (pH 7.5), 150 mM NaCl, 1% NP40, 0.5% deoxy-
cholic acid, 0.1% sodium dodecyl sulfate (SDS), 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride , and
10 mg/mL aprotinin. Cellular debris was removed by cen-
trifugation at 16,060 × g and 4°C for 20 min. An equal
amount of protein of each cell extracts was subjected to
10% SDS-PAGE and the proteins were transferred using
semi-dry blotting to Hybond-ECL membranes (GE
Healthcare, Glattbrugg, Switzerland). Western blot ana-
lysis was performed by probing the membrane with the
following antibodies at the indicated dilution as follows:
anti-rabbit ΔNp63 (1:500; provided by Dr. James DiR-
enzo, Dartmouth Medical School), anti- goat GLI2
(1:200, Santa Cruz Biotechnology, CA, USA), anti-
rabbit GAPDH (1:3000; Santa Cruz Biotechnology) and
species specific horseradish peroxidase conjugated sec-
ondary antibodies (Santa Cruz Biotechnology). Peroxidase
activity was detected using the Immobilon chemilumines-
cence substrate (Millipore, Billerica, MA, USA) and the
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signals were recorded using a VersaDoc Imaging System
(Bio-Rad, Hercules, CA, USA).
RNA interference
p63 siRNA and a non-targeting control siRNA were pur-
chased from Santa Cruz (Santa Cruz Biotechnology).
143B and M132 (1 × 105 cells) were seeded in a 6-well
plate cultured to 70% confluence and then transfected
for 48 h with 20nM p63 siRNA or control siRNA with
Lipofectamine LTX reagent purchased from Invitrogen
(Life Technologies, USA). Transfections were carried out
according to the manufacturer’s instruction. The effi-
ciency of knock-down was analysed by western blotting.
Wound healing assay
SaOS-2-TAp63, SaOS-2- ΔNp6α and SaOS-2-EV cells
were grown to confluence, and cell motility was deter-
mined in an in vitro wound healing assay as described
previously [20]. Motility was determined from the differ-
ence between the wound width at 0 and 24 h and was
calculated from measurements of defined areas of im-
ages of the wounds taken with an AxioCam MRm camera
connected to a Zeiss Observer.Z1 inverted microscope at
4× magnification. The motility of SaOS-2-EV cells or of
untreated cells was defined as 100%.
Cell proliferation assay
Wells of 96 well plates were seeded with 3 × 103 cells
that were allowed to adhere and grow overnight. The
cells were then incubated with 10 μl per well of WST-1
reagent (Roche, Basel, Switzerland) for 3 h and cell
metabolic activity per well was determined according to
a published procedure [21].
Soft-agar colony formation assay
The experiments were carried out in six-well cell culture
plates containing 1.5 ml per well of 0.5% base agar in
cell culture medium supplemented with penicillin,
streptomycin and ampicillin (PSA). Single cell suspen-
sions (2 × 104cells per well) were prepared and added
(1.5 ml per well of cell culture medium containing
0.35% agar and PSA ) added on top of the base agar and
incubated in a humidified atmosphere containing 95%
air and 5% CO2 at 37°C. Twenty-four hours later the top
agar was overlaid with 2 ml/well cell culture medium con-
taining PSA. Cells were incubated for 16 days and the
medium was changed at 3-day intervals. Colonies were
stained with 0.005% crystal violet. Images were acquired
using a Nikon Eclipse E600 camera.
Immunofluorescence
Cells grown on glass coverslips were fixed with 3.7% for-
maldehyde in phosphate-buffered saline (PBS) for 15 min
and permeabilized with 0.2% Triton X-100. The fixed cells
were treated with blocking solution (2% fetal bovine
serum in PBS) and stained with rabbit anti-ΔNp63 (1:500)
together with goat anti-GLI2 (1:400) in blocking solution
incubated at 4°C overnight. The next day, the cells were
washed 3 times with PBS, and stained with Dylight 594-
labeled donkey anti-rabbit, or Cy5-labeled donkey anti-
goat secondary antibodies (Jackson Immuno Research
Laboratories, Inc., Baltimore, Pike West Grove, USA) at
room temperature for 1 h. Nuclear DNA was stained with
0.2 μg/ml 4′,6′-diaminidino-2-phenylindole (Molecular
Probes Inc., Eugene, USA). Fluorescence imaging was
performed using a confocal laser scanning microscope
(SP5, Leica, Heerbrugg, Switzerland) equipped with a
Plan-Apochromat 63 × NA 1.4 oil immersion objective.
Cell cycle analysis
Cell cycle analysis was performed at the Flow Cytometry
Facility at ETH Zurich. The cells were seeded in 10 cm
dishes at a density of 1.0 × 106 cells per dish. Forty-eight
hours after GANT61 treatment SaOS-2-ΔNp6α, SaOS-
2-EV and 143B cells were treated with trypsin, collected
by centrifugation and washed with PBS. Cells were then
fixed in ice cold 70% (v/v) ethanol at 4°C, washed with
PBS and then resuspended in 500 μl of ice cold PI/
RNase Staining Buffer (BD Pharmingen AG, Allschwil,
Switzerland) followed by incubation at 37°C for 30 min
in the dark. The samples were analysed using a fluores-
cence activated cell sorter (FACS) (Calibur, BD, USA).
Doublets were excluded and the percentage of cells
present in each phase of the cell cycle was calculated
using FlowJo software (Ashland, USA).
Chromatin immunoprecipitation (ChIP) assay
To identify whether ΔNp6α binds to the GLI2 promoter,
chromatin immunoprecipitation (ChIP) was performed
using the Millipore ChIP Assay kit (Temecula, CA,
USA) according to the manufacturer’s protocol. The
cells (1 × 107) were cross-linked with formaldehyde and
fragmented by sonication to yield chromatin fragments
of ~500 bp determined using agarose gel electrophoresis.
The cell extracts were treated with Protein A/G agarose
beads before incubation overnight with 10 μg of the ΔNp6α
antibody or the corresponding IgG. The antibody-DNA
complexes were incubated with Protein A/G agarose beads
and cross links were reversed at 65°C in a rotating incu-
bator for 8 h. Immunoprecipitated DNA was analysed
by using qRT-PCR with GLI2 specific primers as follows:
GLI2-1; forward; 5′- GCCACCTGCGTGCTAGA-3′ and
reverse; 5′-GGCCAATGCAACTTTACC-3′, GLI2-2; for-
ward; 5′- ACTCCCATCAATGAGACTTCG-3′ and reverse;
5′- AAGAGAGGGGACCGAGAGG-3′. PCR conditions
were as follows: initial denaturation at 94°C for 5 min,
40 cycles at 95°C for 30 s, 62°C for 30 s, 72°C for 50 s
and final extension at 72°C for 10 min.
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Statistical analysis
Data from triplicate samples were analysed using Graph-
Pad Prism5 software (GraphPad Software, Inc.; La Jolla;
CA, USA) and the differences between means were eval-
uated using the Student’s t- test and P <0.05 was consid-
ered to indicate a significant difference. Kaplan Meier
survival analysis was performed using PASW Statistics
18 (IBM Corporation; New York; USA). The results are
presented as the mean ± standard error of the mean
(SEM).
Ethics statement
All of the studies involving human participates were fully
encoded to protect patient confidentiality and were uti-
lized under a protocol approved by the local ethic com-
mittee (approval reference number StV 41–2005).
Results
ΔNp63α is the predominant p63 isoform expressed by
invasive OS cells
Human p63 generates the- α, β, and γ isoforms of
TAp63 and ΔNp63 with distinct biological functions. To
identify the p63 isoforms expressed by human OS cell
lines, we conducted an expression analysis of various OS
cell lines that represent heterogeneity of tumors in situ.
Transcripts encoding TAp63α were only detected in the
non-invasive human cell lines (HOS and HU09) and
were undetectable in the invasive OS cell lines (LM5,
M8, 143B, M132) (Figure 1A). In contrast, transcripts
encoding ΔNp63α were expressed exclusively in the in-
vasive OS cell lines. Transcripts encoding the β and γ
isoforms of TAp63 and ΔNp63 were undetectable in the
low and high metastatic cell lines.
The specificity of the ΔNp63 isoform-specific antibody
was confirmed by western blotting analysis of lysates
prepared from SaOS-2 cells stably transfected with vec-
tors expressing TAp63α, TAp63γ, ΔNp63α, ΔNp63γ or
with the empty vector. SaOS-2 cells did not detectably
express endogenous p63 or p53 and their isoforms.
Transfected cells expressed ΔNp63α (64 kDa) and
ΔNp63γ (44 kDa) and the ΔNp63 antibodies did not
cross-react with TAp63 isoforms (Additional file 2).
Using this ΔNp63 specific antibody we analysed extracts
from our panel of invasive (LM5, M8, 143B and M132)
and the respective parental non-invasive (SaOS-2,
MG63, HOS and HU09) OS cell lines and determined
that ΔNp63α was expressed only in the invasive OS cell
lines (Figure 1B). We compared the levels of ΔNp63α
and TAp63α in SaOS-2- ΔNp63α and SaOS-2-TAp63
cells as well as the SaOS-2 cells transfected with the
empty vector and with cells that endogenously express
the respective isoform of p63 (143B cells, ΔNp63α; HOS
cells, TAp63). The ectopic and endogenous proteins
were expressed at relatively high levels in the respective
cell lines. Specifically, there was a 90% increase in SaOS-
2- ΔNp63α and SaOS-2-TAp63α protein levels in trans-
duced and control cells compared with SaOS-EV cells
(Additional file 3).
ΔNp63α overexpression in resections of osteosarcoma
patients correlates with worse prognosis
Given the implication of ΔNp63α in tumorigenesis, im-
munohistochemical analysis of ΔNp63α was carried out
to determine whether any correlation of ΔNp63α expres-
sion is related with clinical outcome in OS patient sam-
ples. We analysed the OS tissue microarray (TMA)
based on a two-level grading scheme as described in the
materials and methods. ΔNP63 was expressed in 77% of
all the biopsies and in 53% of the resections. Using
Kaplan–Meier analysis we found no significant correlation
Figure 1 Analysis of the expression of p63 isoforms in human OS cell lines. The human parental low metastatic (non-invasive) SaOS-2,
MG63, HOS and HUO9 cell lines and the respective metastatic (invasive) LM5, M8, 134B and M132 sublines were analysed. A. mRNA levels of p63
splice variants in the indicated OS cancer cell lines were determined using semi quantitative PCR. BxPC3 cells served as the positive control and
GAPDH mRNA levels were used as loading controls. M, molecular size marker lane. B. Protein levels of ΔNp63α in the indicated OS cell lines were
detected using an antibody specific for ΔNp63.
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between ΔNp63 expression in biopsies and survival of
patients (log-rank test, P = 0.727) (data not shown).
However, the prognosis was worse for patients with high
levels of ΔNp63 in resections compared with patients
with low or undetectable expression in resected tumor
tissue (Additional file 4; log-rank test, P = 0.000005).
ΔNp63α mediates the oncogenic phenotype of OS cells
in vitro
To investigate the effects of ΔNp63α expression in OS,
we engineered the non-invasive human osteoblastic
p63−/−//p53−/− null SaOS-2 OS cell line to stably express
ΔNp63α. Because SaOS-2 cells do not express p63 or p53,
we asked whether ectopic expression of ΔNp63α in SaOS-
2 cells (SaOS-2-ΔNp63α) would reveal its functional
significance in OS. SaOS-2 cells transfected with empty
vector (SaOS-2-EV) or the TAp63α expression con-
struct (SaOS-2-TAp63α) served as controls. We tested
whether ΔNp63α expression altered cell motility, prolif-
eration, or both of non- invasive osteoblast cell lines.
The result of the in vitro wound-healing assay demon-
strated that ΔNp63α enhanced cell motility towards the
wound area compared with SaOS-2-TAp63α or SaOS-2-
EV cells. The motility of SaOS-2-ΔNp63α cells was sig-
nificantly higher (P < 0.05) than that of SaOS-2-TAp63α
and SaOS-2-EV cells (Figure 2A and B). Because
anchorage-independent growth characterizes onco-
genic transformation and metastatic potential is indicated
by the ability of cells to form small colonies in soft agar,
we asked whether ΔNp63α regulated anchorage- in-
dependent growth. The number of colonies formed
by SaOS-2-ΔNp63α cells was higher by a factor of 2.6
(P < 0.05) compared with SaOS-2-TAp63α or SaOS-2-
EV cells. This demonstrated that ectopic expression
of ΔNp63α in SaOS-2 cells facilitated anchorage-
independent growth (Figure 2C and D).
We next compared the rates of proliferation of SaOS-2-
ΔNp63α cells with that of SaOS-2-TAp63α and SaOS-2-
EV cells and found that SaOS-2-ΔNp63α cells proliferated
more rapidly (P < 0.05) (Figure 2E). Thus, ectopic expres-
sion of ΔNp63α in SaOS-2 cells significantly enhanced the
expression of phenotypic markers of malignancy.
ΔNp63α-mediated transcript ensemble in osteosarcoma cells
Because ΔNp63α was specifically expressed in invasive
OS cell lines and contributed to their oncogenic pheno-
types, we analysed the ΔNp63α regulated transcriptome
in OS cells to facilitate the identification of genes and
signaling pathways that impart the ΔNp63α-mediated
oncogenic phenotype of OS cells. Therefore, we compared
the global gene expression pattern of SaOS-2-ΔNp63α
and control SaOS-2-EV cells. Both cell lines were grown
under similar conditions and total RNAs from exponen-
tially growing cells were subjected to microarray analysis.
The microarray analysis revealed major differences in the
transcriptional profile of SaOS-2-ΔNp63α cells compared
with that of the control cells. Thus, 196 and 230 genes
were up- or down- regulated by factors of 3 respectively.
A heat map showing the differential expression in de-
scending order of 10 and 3 fold up and down-regulated
genes respectively is shown in Figure 3A and C.
To validate the microarray data, we selected 10 genes
that were highly differentially expressed (Figure 3B and D)
and analysed their expression using qRT-PCR as well as
Figure 2 Overexpression of ΔNp63α enhanced the malignant phenotype of SaOS-2 cells. A. Analysis of the motilities of SaOS-2- ΔNp63α,
SaOS-2-EV and SaOS-2-TAp63α cells in a wound healing assay. Representative photomicrographs of scratch-wounds at the indicated time points
after wounding. Arrows indicate the wound width. B. Quantitative analysis of wound closure in cultures of SaOS-2-EV, SaOS-2-ΔNp63α and
SaOS-2-TAp63α cells. C. Analysis of anchorage-independent growth in soft agar of SaOS-2-ΔNp63α, SaOS-2-TAp63α and SaOS-2-EV cells. Representative
images of colonies stained with 0.005% crystal violet. D. Quantitative analysis of colony formation in soft agar. The numbers of colonies formed
by SaOS-2-EV cells were defined as 1. E. Analysis of proliferation of SaOS-2-ΔNp63α cells, SaOS-2-EV and SaOS-2-TAp63α cells using a WST assay.
Data shown in 2 B, 2 D and 2E represent the mean ± SEM of three independent experiments ( *P < 0.05).
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with DAVID to reveal their functions. Analysis using
the KEGG database yielded specific signaling pathways,
molecular functions, and biological processes that are
involved the network of differentially expressed genes
(Figure 3E and F). Hedgehog signaling genes were enriched
by a factor of 5 and the expression of Hh signaling pathway
components GLI2, BMP4, BMP5, PTCH1 and IHH were
highly regulated by ΔNp63α.
ΔNp63α induces GLI2 expression in OS cells by binding to
the GLI2 promoter
The results of the transcriptional analysis presented above
supports the conclusion that ΔNP63α specifically activates
Hh signaling in OS cells. Moreover, GLI2 is implicated in
OS and targeting GLI2 has been suggested for treating
OS. We next investigated whether ΔNp63α regulates the
transcription of GLI2. We conducted qRT-PCR analysis of
SaOS-2-ΔNp63α cells and found that GLI2 mRNA levels
were higher by a factor of 4.5 compared with SaOS-2-EV
cells (Figure 4A), which is consistent with the microarray
data and the western blotting analysis shown in Figure 4B.
We next determined the effect of a p63 siRNA on the OS
cell lines (143B and M132) that express high levels of en-
dogenous ΔNp63α. The level of ΔNp63α protein was de-
creased by approximately 80% in p63 siRNA-transfected
143B and M132 cells compared with cells transfected with
control siRNA (Figure 4C) and was accompanied by a de-
crease in the level of endogenous GLI2 (Figure 4C and D).
In contrast, the level was unchanged in cells transfected
with control siRNA. We determined whether TAp63α also
regulate GLI2 expression by using siRNA approach to in-
hibit p63 expression in OS cells (HOS, HU09) that express
endogenous TAp63. GLI2 levels did not change when
TAp63 expression was inhibited as shown by the western
blot (Additional file 5) thereby indicating that GLI2 is not
regulated by TAp63.
We asked whether the silencing of ΔNp63α altered the
levels of expression of genes that were identified as up-
Figure 3 Microarray analysis to detect differential gene expression in SaOS-2- ΔNp63α cells. Hierarchical clustering of differentially
expressed genes revealed by microarray analysis in SaOS-2- ΔNp63αcells compared with SaOS-2-EV cells. The heat maps depict the fold-change
of up- (A) and down-regulated (C) genes in SaOS-2-ΔNp62α compared with SaOS-2-EV cells in descending order of 10 to 3. Quantitative RT-PCR
validation of the microarray results obtained for indicated up (B) and down-regulated (D) genes. E. Transcript enrichment in SaOS-2-ΔNp63α cells
grouped by functional related terms from the KEGG pathway analysis. F. Genes enriched in Hh signaling pathway are highlighted.
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regulated using microarray analysis. We selected the top
three genes (IFITM5, SMPD3, and ECEl1) that were up-
regulated in SaOS-2-ΔNp63α cells. 143B and M132 cells
were selected which expressed endogenous ΔNp63α and
p63 expression was inhibited using the cognate siRNA.
There was no significant difference in the mRNA levels
of IFITM5, SMPD3, and ECEl1 between transfected and
control cells (Additional file 6). These data may indicate
that those genes are indirectly regulated by ΔNp63α.
We next analysed whether ΔNp63α bound to the GLI2
promoter. We identified the p63 binding consensus se-
quence (T/A) A (T) ACA (T) TGT (T/A) T [22] in the
promoter region of GLI2 (Figure 4E). To determine
whether ΔNp63α bound the GLI2 promoter, we
performed ChIP analysis of SaOS-2-ΔNp63α cells using
primer sets that amplify the GLI2 promoter regions har-
boring the p63 consensus sequence (primer GLI2-1)
and the TSS sites (primer GLI2-2) (Additional file 7).
The results of ChIP experiments demonstrated that
ΔNp63α bound specifically to the GLI2 promoter region
(Figure 4F). The binding specificity was indicated by the
controls using the GAPDH promoter and non-specific
IgG and the lack of detection of the ΔNp63α-GLI2 pro-
moter complex in SaOS-2-EV cells.
The coordinate regulation of the expression of GLI2
and ΔNp63α in invasive and the cognate parental non-
invasive OS cell lines was further confirmed by the
results of qRT-PCR analysis (Figure 5A). The levels of
mRNAs encoding ΔNp63α and GLI2 were up-regulated
only in the invasive cell lines. To gain further insight into
the functional correlation between ΔNp63α and GLI2,
we analysed their expression in 143B cells that ex-
pressed endogenous ΔNp63α and GLI2 and in SaOS-
2-ΔNp63α cells. Double-immunofluorescence assays
detected ΔNp63α and GLI2 in both cell lines suggest-
ing the presence of a ΔNp63α-GLI2 signaling axis in
OS cells (Figure 5B). Neither protein was detected in
SaOS-2-EV cells.
GLI2 mediates the oncogenic phenotype of ΔNp63α in
OS cells
We next asked whether GLI2 mediated the oncogenic
activities of ΔNp63α by treating SaOS-2-ΔNp63α cells
with the small molecule GANT61 that specifically in-
hibit the binding of GLI1 and GLI2 to DNA and inhibits
downstream signaling through the Hh pathway [23].
GLI2 expression was significantly inhibited in SaOS-2-
ΔNp63α cells treated with 20 μM GANT61 (Figure 6A).
In contrast, the levels of ΔNp63α were not affected
(Additional file 8).
We next tested whether inhibiting GLI2 expression with
20 μM GANT61 affected the enhanced colony formation
and proliferation of SaOS-2-ΔNp63α cells. GANT61 treat-
ment decreased colony formation by SaOS-2-ΔNp63α
cells to the level of SaOS-2-EV and SaOS-2-TAp63 cells
(Figure 6B). Moreover, GANT61 did not significantly in-
hibit colony formation by the latter two cell lines. Simi-
larly, treatment of SaOS-2-ΔNp63α cells with GANT61
reduced their proliferation rate to that of SaOS-2-EV and
SaOS-2-TAp63α cells (Figure 6C).
Treatment with GANT61 increased the percentage of
cells in the G1 phase from 60.2 to 67.8%, from 52.6 to
75.6% and from 60.3 to 80.1% in SaOS-2-EV, SaOS-2-
ΔNp63α and 143B cells respectively (Figure 6D). Although
cell cycle arrest in SaOS-2-EV cells treated with GANT61
was not very prominent, the increase in the percentage of
cells arrested in G1 phase was significantly higher in
SaOS-2-ΔNp63α and 143B cells (Additional file 9).
Figure 4 ΔNp63α activates GLI2 transcription. A. Real time PCR
analysis of total RNA isolated from SaOS-2-ΔNp63α and SaOS-2-EV
cells shows upregulation of GLI2 expression in SaOS-2-ΔNp63α cells.
*P value < 0.05 (n = 3). B. Western blot analysis of cell lysates
prepared from SaOS-2-EV and SaOS-2-ΔNp63α cells show the
elevated expression of GLI2 in SaOS-2-ΔNp63α cells. C. Western blot
analysis of ΔNp63α and GLI2 expression in lysates prepared from
143B and M132 cells after transfection with control or p63 siRNAs.
D. Quantification of relative GLI2 expression is shown in panel D.
*P value < 0.05 (n = 3). E. The GLI2 promoter and transcription
initiation region and p63 consensus-binding site (essential sequences
underlined) probed using chromatin immunoprecipitation (ChIP).
F. ChIP analysis of occupancy of the GLI2 promoter by ΔNp63α using
control IgG or an antibody against ΔNp63 (anti- ΔNp63) in SaOS-2-EV
and SaOS-2-ΔNp63α cells as indicated. Amplification of the GLI2 and
GAPDH promoter regions using GLI2-1 and GLI2-2 primer sets was
analysed using agarose gel electrophoresis. Input control lanes, IgG
and GAPDH controls are shown.
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Consistent with the cell cycle data, we found that
treating SaOS-2-ΔNp63α cells with GANT61 decreased
the expression of mRNAs encoding Cyclin D1 and SKP2
but not that of n-MYC. Treating SaOS-2-EV cells with
GANT61 did not significantly change the levels of any
of these transcripts (Figure 6E), suggesting that the ex-
pression of ΔNp63α and GLI2 regulates the cell cycle of
OS with a more aggressive phenotype. Taken together,
our findings demonstrate that the induction of GLI2 ex-
pression by ΔNp63α mediates the oncogenic phenotype
of OS cells.
Discussion
Here, we studied the role of ΔNp63α in determining the
oncogenic potential of OS cells and identified novel
genes targeted by ΔNp63α. Initial studies of ΔNp63 led
to the hypothesis that upregulation of its expression
counteracts p53 functions. However, evidence indicated
that ΔNp63α induced the proliferation of cancer cells
through the transactivation of certain target genes [24].
Yang et al. identified p63 target genes that were involved in
cell adhesion, proliferation, death, and were components of
the Wnt and TGFβ signaling pathways [25]. p63 has been
implicated in cell adhesion programs involved in tumor in-
vasion and cell migration [26]. Of all ΔNp63 isoforms,
ΔNp63α appears to have the most potent effects, which
may be attributed to the presence of sterile α motifs (SAM)
and post SAM domains that recruit other proteins or fold
up and inactivate the TA domains [7,27].
ΔNp63α is overexpressed in squamous carcinomas,
cancers of epithelial origin such as head and neck and
lungs and may enhance cell growth by counteracting
p53-mediated growth arrest and apoptosis [28]. Bid
et al. suggest that ΔNp63α contributes to the progres-
sion of OS and neuroblastoma by inducing tumor angio-
genesis, because they found that lung sections from
patients with OS express high levels of ΔNp63α com-
pared with the primary lesions from the same patients
and that this promotes secretion of IL-6 and IL-8 to
Figure 5 Analysis of ΔNp63α and GLI2 expression in OS cell
lines. A. qRT PCR analysis of ΔNp63α and GLI2 mRNA expression in
a panel of OS cell lines as indicated. GAPDH mRNA was used as an
internal control. B. Immunocytochemical analysis of ΔNp63α and
GLI2 expression in SaOS-2-ΔNp63α, SaOS-2-EV and 143B cells.
Figure 6 GLI2 mediates the oncogenic potential of ΔNp63α in
OS cells. A. Cell lysates of SaOS-2-EV and SaOS-2-ΔNp62α cells
untreated or treated with 20 μM GANT61 were analysed using
western blotting with an anti- GLI2 antibody. B. GANT61 (20 μM)
reversed enhanced anchorage-independent growth in SaOS-2-ΔNp62α
cells determined using a soft agar assay and (C) proliferation was
assessed using a WST assay. Data represent the mean ± SE of three
independent experiments. *P value < 0.05. D. SaOS-2-EV, SaOS-2-
ΔNp62α and 143B cells were treated with 20 μM GANT61 and
subjected to cell cycle analysis 24 h after drug treatment. SaOS-2-
ΔNp62α and 143B cells exposed to GANT61 were arrested in G1
phase. E. Real time PCR analysis of mRNA expression of cell-cycle
related genes in SaOS-2-EV and SaOS-2-ΔNp62α cells. 24 h treatment
with GANT61 reduced the levels of CyclinD1 and SKPC1 but not
n-MYC. *P value < 0.05 (n = 3).
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induce angiogenesis. They hypothesized that ΔNp63α
provides the cells with a gain of function that leads to
malignant transformation. Moreover, silencing of ΔNp63α
expression in highly invasive OS cell lines significantly
reduces proliferation and anchorage independent
growth [10]. In their study elevated levels of ΔNp63
were detected in 57% of the OS samples; however,
these data were not correlated to any clinical parame-
ters. Our TMA analysis of expression of ΔNp63 in
high-grade OS patients showed that prognosis was
worse in resections while no significant correlation
was found for ΔNp63 expression in biopsies.
Here, we report that ΔNp63α is the major p63 isoform
expressed in OS cell lines and that GLI2 is regulated by
ΔNp63α to promote its oncogenic properties. By analys-
ing human OS cell lines that differ in invasive properties,
we found that ΔNp63α is overexpressed only in invasive
OS cell lines. We further demonstrate that enforced ex-
pression of ΔNp63α in low metastatic SaOS-2 OS cell
lines, which expressed low levels of endogenous p63
protein and mRNA, increased the cell proliferation rate,
cell motility and enhanced anchorage independent
growth. Because proliferation and colony formation are
important cellular properties that contribute to the cas-
cade that leads to metastasis, our findings underscore
the importance of ΔNp63α expression in the malignant
progression of OS.
SaOS-2-ΔNp63α cells did not undergo apoptosis (data
not shown), in contrast to a report that ectopic expres-
sion of ΔNp63α in p53/p63 null non-small lung cancer
cells induces apoptosis and cell cycle arrest [29]. How-
ever, our observation agrees with the results of a study
of pancreatic ductal adenocarcinoma (PDAC) where
overexpression of ΔNp63α in the p63 null PDAC cell
line PANC-1 did not induce apoptosis [30]. King et al.
reported that overexpression of ΔNp63α in mouse kera-
tinocytes maintained proliferation under conditions that
normally induce growth arrest and differentiation [31].
To enhance our understanding of pathogenesis of OS
and to define the molecular pathways that are activated
by ΔNp63α, we conducted microarray analysis to deter-
mine the transcription profile in SaOS-2 cells transfected
with ΔNp63α expression vector. The search for p63 tar-
get genes identified many pathways regulated by p63
[32,33], and most of the upregulated genes were identi-
fied in the present study. Analysis using DAVID grouped
the up-regulated genes into clusters according to their
Gene Ontology (GO) functions and identified compo-
nents of Hh signaling pathway and GLI2 in particular as
a novel transcriptional target of ΔNp63α.
Mohseny et al. reported that Hh pathway activity var-
ied widely among OS cell lines and did not correlate
with the patient survival [34]. However, Lo et al. ana-
lysed Hh pathway genes in 43 human primary high-
grade OS samples and found that expression levels of
genes encoding IHH, PTCH1 and GLI genes but not
SMO were higher in tumors. Activation of ligand
dependent (IHH-PTCH1 co-expression), and ligand in-
dependent (SMO, PTCH1, GLI) signaling might lead to
Hh activation in OS. Moreover, the high levels of IHH
may lead to larger tumor size, a prognostic factor of OS
and indicate that activation of Hh signaling is required
for OS progression [35]. GLI2 expression is required for
the growth of OS cells and GLI2 is overexpressed in OS
biopsy specimens and OS cell lines [36]. Inhibiting ex-
pression of GLI2 in 143B cells transfected with GLI2-
shRNA inhibited OS growth and reduced tumor volume
12 weeks after inoculation in nude mice [37].
The current study determined whether GLI2 was regu-
lated by ΔNp63α in OS. To investigate the functional as-
sociation of ΔNp63α and GLI2 in OS, we used siRNA
technology to silence the expression of p63 in invasive
OS cells that expressed high levels of endogenous
ΔNp63α. Bid et al. demonstrated that silencing endogen-
ous ΔNp63α in highly proliferating tumorigenic OS cell
lines reduced cell proliferation and colony formation.
Injecting nude mice with an invasive OS cell line trans-
duced with a ΔNp63 expression vector reduced tumor
formation compared with the control thereby establish-
ing the importance of ΔNp63α in OS metastasis [10]. In
the present study, inhibition of expression of ΔNp63α in
invasive OS cells downregulated GLI2 expression. More-
over, we determined that ΔNp63α binds directly to the
GLI2 promoter which explains how GLI2 expression is
regulated by ΔNp63α.
Using an inhibitor (GANT61) of GLI2, we showed
here that GLI2 mediated the oncogenic effects of
ΔNp63α. Because GANT61 inhibits GLI1 as well as
GLI2 induced transcription, additional studies are re-
quired to determine the contributions of individual
GLI family members to the malignant phenotype of
OS. GLI1 is overexpressed and GLI2 is downregulated
in SaOS-2 cells [38,39]. Interestingly, SaOS-2 cells are
also reported to express high levels of GLI2 [40]. Al-
though GLI1 and GLI2 function as transcriptional acti-
vators of the Hh pathway, they have nonredundant
roles in osteosarcoma [38].
Taken together, our studies indicate an important role
of the ΔNp63α-GLI2 axis in OS progression. Our data
warrant further investigations of treatment of patients
with OS with high levels of GLI2 expression with inhibi-
tors of ΔNp63α signaling.
Conclusions
In summary, ΔNp63α regulates the expression of GLI2
and is involved in the metastasis of osteosarcoma. Our
data contribute to a better understanding of the role of
the transcription factors, ΔNp63α and GLI2 in OS and
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suggest that the ΔNp63α-GLI2 axis may serve as a target
for therapy of osteosarcoma.
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